Agenus Inc. shares surge 19.54% intraday after positive clinical data and strategic partnership.

Agenus Inc. surged 19.54% intraday, following the announcement of positive data for its iNKT cell therapy agenT-797 in refractory testicular cancer patients, a strategic collaboration with Zydus Lifesciences for $141 million to advance BOT/BAL therapy and biologics production, and the release of 42% two-year survival rate data for its BOT/BAL combination in MSS colorectal cancer patients at the ESMO GI conference.